BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2026 9:23:57 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-11-27 02:20 |
|
Peer-Review Started |
|
2025-11-27 02:20 |
|
First Decision by Editorial Office Director |
|
2025-12-09 10:06 |
|
Return for Revision |
|
2025-12-10 12:41 |
|
Revised |
|
2025-12-23 14:58 |
|
Publication Fee Transferred |
|
2025-12-26 07:22 |
|
Second Decision by Editor |
|
2026-01-26 02:51 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-26 08:46 |
|
Articles in Press |
|
2026-01-26 08:46 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-24 09:31 |
|
Publish the Manuscript Online |
|
2026-06-09 09:23 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Adjuvant programmed death-1 inhibition combined with chemotherapy in resected pancreatic cancer: A real-world cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tang Cao, Xiang-Liang Deng, Jin Xiao, Xiao-Hong Tao, Xue-Lian Xiang, Man Qiu and Xiao-Yan Liang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82273125 |
| Natural Science Foundation of Chongqing |
CSTB2022NSCQ-MSX0803 |
| High-level Medical Reserved Personnel Training Project of Chongqing |
2023GDRC009 |
|
| Corresponding Author |
Xiao-Yan Liang, Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. lxyan@hospital.cqmu.edu.cn |
| Key Words |
Pancreatic ductal adenocarcinoma; Programmed death-1 inhibitor; Adjuvant therapy; Recurrencefree survival; Immunotherapy; Real world study |
| Core Tip |
This real-world retrospective cohort study investigated the potential role of programmed death-1 (PD-1) inhibitor-based adjuvant therapy in patients with resected pancreatic ductal adenocarcinoma (PDAC), a population characterized by high recurrence risk after surgery. By comparing adjuvant chemotherapy alone with chemotherapy combined with PD-1 inhibition, this study demonstrated improved recurrence-free outcomes without an increase in severe treatment-related adverse events. These findings provide real-world clinical evidence supporting the feasibility of incorporating immunotherapy into postoperative adjuvant treatment strategies for resected PDAC. |
| Publish Date |
2026-06-09 09:23 |
| Citation |
Cao T, Deng XL, Xiao J, Tao XH, Xiang XL, Qiu M, Liang XY. Adjuvant programmed death-1 inhibition combined with chemotherapy in resected pancreatic cancer: A real-world cohort study. World J Gastrointest Oncol 2026; 18(6): 117057
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i6/117057.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i6.117057 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
